- ICH GCP
- Rejestr badań klinicznych w USA
- Strona Badania kliniczne Nct
Study to Evaluate the Viral Load Reduction of a Single Dose of Plitidepsin in Adult Patients With COVID-19
Open Label, Randomized Phase II Study to Evaluate the Viral Load Reduction of a Single Administration of Plitidepsin in Adult Patients With COVID-19 at Discharge From Emergency
Sponsorzy |
Główny sponsor: PharmaMar Współpracownik: Apices Soluciones S.L. |
---|---|
Źródło | PharmaMar |
Krótkie podsumowanie | The main objective of this study is to evaluate the efficacy and safety of a single dose of plitidepsin in order to reduce the viral load and symptoms recovery after discharge from Emergency. |
szczegółowy opis | More than a year after the appearance of the new SARS-COV-2 coronavirus, the search continues for an effective treatment to reduce the symptoms and infectivity of a pandemic that has left behind more than 120 million cases and more than 2.5 million deaths. Plitidepsin is an approved multiple myeloma drug in Australia that in both preclinical and clinical studies has shown a clear antiviral effect against SARS.COV-2 and, in this study, we propose to evaluate the efficacy of a single dose of plitidepsin 7.5 mg administered in 90 minutes through decreasing viral load at day 6 and symptoms recovery at day 14 with after the patient is discharged from Emergency. |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ogólny stan | Not yet recruiting | ||||||||||||||||||||||
Data rozpoczęcia | 2021-04-15 | ||||||||||||||||||||||
Data zakończenia | 2021-10-15 | ||||||||||||||||||||||
Podstawowa data ukończenia | 2021-10-15 | ||||||||||||||||||||||
Faza | Phase 2 | ||||||||||||||||||||||
Typ studiów | Interventional | ||||||||||||||||||||||
Wynik podstawowy |
|
||||||||||||||||||||||
Wynik drugorzędny |
|
||||||||||||||||||||||
Rekrutacja | 122 |
Stan: schorzenie | |
---|---|
Interwencja |
Rodzaj interwencji: Drug Nazwa interwencji: Plitidepsin Opis: Single dose of 7.5 mg plitidepsin administered as a 90-minute infusion (±10 minutes) plus symptomatic treatment according clinical practice: If muscular pain, arthralgia, and fever > 38ºC: Paracetamol 1 g/8 hours 7-10 days. If symptoms persist: Metamizole 500 mg /8 hours. If diarrea of > 10 stools: Loperamide as per SmPC. Etykieta grupy ramion: Plitidepsin plus symptomatic treatment Rodzaj interwencji: Drug Nazwa interwencji: Symptomatic Treatment Opis: Symptomatic treatment according clinical practice: If muscular pain, arthralgia, and fever > 38ºC: Paracetamol 1 g/8 hours 7-10 days. If symptoms persist: Metamizole 500 mg /8 hours. If diarrea of > 10 stools: Loperamide as per SmPC. Etykieta grupy ramion: Symptomatic treatment |
Kwalifikowalność |
Kryteria:
Inclusion Criteria: 1. Patient who agrees to participate in the study by signing the informed consent. 2. Men and women aged ≥18 years and <80 years 3. Acute COVID-19 infection (onset of symptoms within the previous 5 days), diagnosed at emergency visit confirmed by 1. Positive antigen test for SARS COV2, or 2. PCR-RT test obtained on nasopharyngeal swab or by antigen test. positive for SARS COV2. 4. Clinically stable patient defined as: 1. Heart rate < 100 beats per minute 2. Respiratory rate < 24 breaths per minute. 3. Axillary temperature < 37.2 ºC 4. Systolic blood pressure >90 mmHg 5. SaO2 >92%. 6. Adequate level of consciousness 5. Patient without radiological criteria of severity: without radiological lung disease or with mild pneumonia confirmed by chest X-ray and without signs of severity (SaO2 ambient air >92%. FINE criteria ≤3). 6. Men and women with reproductive capacity must agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the administration of plitidepsin. 7. Women participating in the study with reproductive ability must have a negative pregnancy test at enrollment. Exclusion Criteria: 1. Patients participating in some other clinical trial for COVID-19 infection. 2. Patients requiring hospital admission. 3. Patients with evidence of pneumonia on recent imaging within the previous 24 hours, with respiratory failure (PO2<60 or SatO2 <92), and with a FINE score > 3. 4. Patient without analytical stability: 1. Haemoglobin < 9 g/dL. 2. Neutrophils < 1000/mm3. 3. Platelets < 100,000/mm3. 4. Lymphopenia < 800/μL. 5. GOT / GPT > 3 X ULN. 6. Bilirubin > 1 X ULN. 7. CPK > 2.5 X ULN. 8. Creatinine clearance < 30 ml/min. 9. BUN > 20 mg/dl. 10. Troponin elevation > 1.5 x ULN. 5. Patients who will not receive the vaccine for at least 30 days following emergency discharge. 6. Patients who are receiving or have received treatment with chloroquine and derivatives in the previous 50 days. 7. Patients living in an isochrone of more than 30 minutes by car, which precludes follow-up at home and the collection of the necessary samples at repeated visits. 8. Patients for whom it is foreseen that follow-up is not going to be possible for any reason (absence from home, inability to open the door at the request, etc.). 9. Patients with any known alteration of immunity including current treatment with corticoids, or with monoclonal antibody or any drug that alters the patient's immunity. 10. Clinically relevant heart disease (NYHA >2). 11. Relevant electrocardiographic abnormalities: - Sinus bradycardia (<50 beats/min), sinus nodal dysfunction (sick sinus disease), atrioventricular block of any degree (PR >200 msec), or any other bradyarrhythmia (<50 beats/min), except for patients with permanent pacemakers; - Cardiac infarction, cardiac surgery or cardiac insufficiency episode within the last 6 months; or - QT interval corrected using Fridericia's formula (QTcF) prolongation >450 msec for males or >470 msec for females, based on triplicate ECG at screening. 12. Hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol). 13. Patients requiring or being treated with potent CYP3A4 inhibitors and inducers. 14. Patients with pulmonary thromboembolism or deep vein thrombosis, who would require new treatment with anticoagulants, which could interfere with study results by including an accepted COVID treatment in one of the arms. 15. Patients who for any reason should not be included in the study according to the evaluation of the research team. Płeć: All Minimalny wiek: 18 Years Maksymalny wiek: 80 Years Zdrowi wolontariusze: No |
Ogólnie urzędnik |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ogólny kontakt | Informacje kontaktowe są wyświetlane tylko wtedy, gdy badanie rekrutuje uczestników. | |||||||||||||||
Lokalizacja |
|
Kraje lokalizacji |
Spain |
---|---|
Data weryfikacji |
2021-03-01 |
Odpowiedzialna impreza |
Rodzaj: Sponsor |
Słowa kluczowe | |
Ma rozszerzony dostęp | No |
Liczba ramion | 2 |
Grupa Arm |
Etykieta: Plitidepsin plus symptomatic treatment Rodzaj: Experimental Opis: Plitidepsin 7.5 mg plus paracetamol, metamizole, and loperamide if applicable Etykieta: Symptomatic treatment Rodzaj: Active Comparator Opis: Paracetamol, metamizole, and loperamide if applicable |
Akronim | APLIDURG |
Badanie informacji o projekcie |
Przydział: Randomized Model interwencji: Parallel Assignment Podstawowy cel: Treatment Maskowanie: None (Open Label) |
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Badania kliniczne na COVID-19
-
NCT05808231Rekrutacyjny
-
NCT05808322Jeszcze nie rekrutuję
-
NCT05808413Jeszcze nie rekrutujęWarunki: Vaccine Refusal, COVID-19
-
NCT05808400RekrutacyjnyWarunki: Long COVID-19 Syndrome
-
NCT05808361ZakończonyWarunki: Rehabilitation, Pneumonia, Viral, COVID-19, Quality of Life
-
NCT05808348RekrutacyjnyWarunki: Pain, Fear, Falling, Physical Activity, COVID-19, Aged
-
NCT05803395Jeszcze nie rekrutujęWarunki: Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
-
NCT05801341Jeszcze nie rekrutujęWarunki: COVID-19, Diagnostic Test
-
NCT05799495Jeszcze nie rekrutuję
-
NCT05799482Jeszcze nie rekrutuję